Onkológia 5/2012

Myelofibróza – posúdenie nových liečebných možností

Treatment options for myelofibrosis as a myeloproliferative neoplasms are limited. Allogeneic hematopoietic stem cell transplant (HSCT) is the only one potentially curative option for MF. Conventional therapies are palliative, therefore there is an urgent need for new treatment strategies to be developed. The discovery of deregulation JAK/STAT pathway as main charakteristics BCR-ABL-negative MPNs has led to a resurgenece of medical interest in JAK-STAT targeted treatment modalities. First of JAK inhibitors ruxolitinib represents another example of an increasing trend in oncology where a detailed understanding of mechanisms of a disease allows the drug to be directed towards specific molecular pathways. Ruxolitinib is the most promising agent in the experimental treatment of MF. The risk adapted treatment and the right timing improved quality of life of patient and ultimately prolongs survival with MF.

Keywords: myelofibrosis, myeloproliferative neoplasms, risk adapted treatment, Janus kinasa, JAK inhibitors, ruxolitinib.